ClinicalTrials.gg
CompletedNCT03937479Updated Nov 20, 2020Results posted

Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD

A Phase 2 interventional study of Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium and Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium in COPD, sponsored by Verona Pharma plc. Completed at 50 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-11-20.

Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
416
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc — 1 open to participants now, 3 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Merck & Co., Inc.

Enrollment
7th of 26
416 · median 89
Started
2019
with 1 other
Phase 2
18 of 26
none open now
Registered
16th of 26
by date

Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc, this one is the 7th largest by enrollment, is one of 2 that started in 2019, is one of 18 in phase 2, and was the 16th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the dose response of RPL554 in patients with moderate to severe CHRONIC OBSTRUCTIVE PULMONARY DISEASE that are still symptomatic despite treatment with a stable background of tiotropium over 4 weeks of treatment. This study is intended to support optimal dose selection for a Phase III program evaluating RPL554 as an add-on treatment to standard of care therapy.

Read the detailed description

This is a Phase IIb, randomized, double-blind, placebo controlled, multiple dose, parallel group study to investigate the effects of 4 weeks of treatment with nebulized RPL554 (at different dose levels) compared to placebo in patients with moderate to severe CHRONIC OBSTRUCTIVE PULMONARY DISEASE on a stable background therapy of open-label tiotropium. The study comprises seven visits: Pre-screening (Visit 0), Screening (Visit 1) and then a Treatment Period consisting of Randomization (Visit 2), and weekly visits for 4 weeks (Visit 3 to Visit 6).

03

Conditions studied

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign an document indicating they understand the purpose of and procedures required for the study and are willing to participate in the study.
  • Male or female aged between 40 and 80 years inclusive, at the time of informed consent.
  • Must agree to meet the following from the first dose up to 1 month after the last dose of study medication:

    • If male:

      • Not donate sperm
      • Either: be sexually abstinent in accordance with a patient's usual and preferred lifestyle (but agree to abide by the requirements below should their circumstances change)
      • Or: use a condom with all sexual partners. If the partner is of the condom must be used with spermicide and a second reliable form of contraception must also be used (e.g., diaphragm/cap with spermicide, established hormonal contraception, intra-uterine device)
    • If female:

      • be of non-childbearing potential or use a highly effective form of contraception
  • Have a 12-lead recording at Screening showing the following (and no changes in the pre-dose value at the first treatment deemed by the Investigator):

    • Heart rate between 45 and 90 beats per minute
    • corrected for heart rate using Fridericia's formula (QTcF) ≤450 msec for males, and ≤ 470 msec for females
    • QRS interval ≤ 120 msec
    • No clinically significant abnormality including morphology (e.g., left bundle branch block, atrio-ventricular nodal dysfunction, ST segment abnormalities consistent with ischemia)
  • Capable of complying with study restrictions and procedures, including ability to use the nebulizer correctly.
  • (BMI) between 18 and 35 kg/m2 (inclusive) with a minimum weight of 45 kg.
  • diagnosis: Patients with a diagnosis of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines (Celli and MacNee, 2004) with symptoms compatible with COPD for at least 1 year prior to Screening.
  • Ability to perform acceptable and reproducible spirometry.
  • Post-bronchodilator (four puffs of albuterol) spirometry at Screening demonstrating the following:

    • / FVC ratio of ≤0.70
    • FEV1 ≥30% and ≤70% of predicted normal* *National Health and Nutrition Examination Survey (NHANES) III (Hankinson et al, 1999) will be used as the reference for normal predicted values.
  • Clinically stable COPD in the 4 weeks prior to Screening (Visit 1) and during the period between Visits 1 and 2.
  • A score of ≥2 on the modified Medical Research Council (mMRC) dyspnea scale at Screening.
  • A chest X-ray (posterior-anterior) at Screening, or in the 12 months prior to Screening showing no clinically significant abnormalities unrelated to COPD.
  • Meet the concomitant medication restrictions and be expected to do so for the rest of the study.
  • Current and former smokers with smoking history of ≥10 pack years.
  • Capable of withdrawing from long acting bronchodilators (other than tiotropium) for the duration of the study, and short acting bronchodilators for 6 hours prior to dosing.

Exclusion criteria

Exclusion Criteria:

  • A history of life-threatening including Intensive Care Unit admission and/or requiring intubation.
  • COPD exacerbation requiring oral or parenteral , or lower respiratory tract infection requiring antibiotics, within 3 months of Screening or prior to the first treatment.
  • A history of one or more hospitalizations for COPD or pneumonia within 6 months of Screening or prior to the first treatment.
  • Intolerance or to albuterol, tiotropium or other muscarinic receptor antagonists.
  • Other respiratory disorders: Patients with a current diagnosis of asthma, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, uncontrolled or unstable sleep apnea, known alpha-1 antitrypsin deficiency, core pulmonale, pulmonary hypertension or other active pulmonary diseases.
  • Previous lung resection or lung reduction surgery.
  • Pulmonary rehabilitation, unless such treatment has been stable from 4 weeks prior to Screening and remains stable during the study.
  • Oral therapies for COPD (e.g. oral steroids, theophylline, and roflumilast) or antibiotics within 3 months prior to Screening, or ICS therapy within 4 weeks prior to Screening
  • Prior exposure to RPL554.
  • History of, or reason to believe a patient has, drug or alcohol abuse within the past 5 years.
  • Received an experimental drug within 30 days or five half-lives, whichever is longer.
  • Women who are pregnant or breast-feeding.
  • Patients with uncontrolled disease including, but not limited to, endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, hematological, urological, immunological, psychiatric, or ophthalmic diseases that the Investigator believes are clinically significant. This includes any hepatic disease or moderate to severe renal impairment.
  • Documented clinically significant cardiovascular disease such as: any history of arrhythmias, angina, recent (\<1 year) or suspected myocardial infarction, congestive heart failure, unstable or uncontrolled hypertension, or diagnosis of hypertension within 3 months prior to Screening.
  • Use of non-selective oral β-blockers.
  • Major surgery (requiring general anesthesia) within 6 weeks prior to Screening, lack of full recovery from surgery at Screening, or planned surgery through the end of the study.
  • Required use of oxygen therapy, even on an occasional basis.
  • History of of any organ system within 5 years, with the exception of localized skin cancers (basal or squamous cell).
  • Clinically significant abnormal values for laboratory safety tests (hematology, blood chemistry, viral serology or urinalysis) at Screening, as determined by the Investigator. In particular, or aspartate aminotransferase cannot be more than twice the .
  • Patients with conditions which are sensitive to antimuscarinic effects such as narrow angle glaucoma, urinary retention, prostatic hypertrophy, or bladder neck obstruction.
  • Current marijuana use (all forms).
  • A disclosed history or one known to the Investigator, of significant non-compliance in previous studies or with prescribed medications.
  • Any other reason that the Investigator considers makes the patient unsuitable to participate.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
416 participants (actual)

Study arms

  • Experimental
    RPL554 0.375 mg twice daily

    RPL554 0.375 mg twice daily

    Drug: Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium

  • Experimental
    RPL554 0.75 mg twice daily

    RPL554 0.75 mg twice daily

    Drug: Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium

  • Experimental
    RPL554 1.5 mg twice daily

    RPL554 1.5 mg twice daily

    Drug: Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium

  • Experimental
    RPL554 3.0 mg twice daily

    RPL554 3.0 mg twice daily

    Drug: Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium

  • Placebo comparator
    Placebo twice daily

    Placebo twice daily

    Drug: Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium

Interventions

  • DrugEnsifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium

    Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● RPL554 0.375 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.

  • DrugEnsifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium

    Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● RPL554 0.75 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.

  • DrugEnsifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium

    Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● RPL554 1.5 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.

  • DrugEnsifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium

    Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● RPL554 3.0 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.

  • DrugEnsifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium

    Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● Placebo twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.

06

What researchers measure

Primary outcomes

  1. Least Square (LS) Mean Change From Baseline Forced Expiratory Volume in 1 Second (FEV1) to Peak FEV1 at Week 4

    Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and peak FEV1 was defined as the maximum value in the 3 hours after dosing. Spirometry assessments were performed in accordance with American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines.

    Time frame: Baseline and Week 4

Secondary outcomes

  1. LS Mean Change From Baseline FEV1 to Average Area Under the Curve Over 3 Hours (AUC0-3h) FEV1 on Day 1 and at Weeks 1 to 4

    Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and average AUC0-3h FEV1 was defined as area under the curve over 3 hours of the FEV1, divided by 3 hours. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

    Time frame: Baseline (30 minutes before first administration on Day 1); 30 minutes and 1, 2, and 3 hours post-dose on Day 1 and Weeks 1, 2, 3 and 4

  2. LS Mean Change From Baseline FEV1 to Average Area Under the Curve Over 12 Hours (AUC0-12h) FEV1 on Day 1 and at Week 4

    Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and average AUC0-12h FEV1 was defined as area under the curve over 12 hours of the FEV1, divided by 12 hours. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

    Time frame: Baseline (30 minutes before first administration on Day 1); 30 minutes and 1, 2, 3, 4, 6, 8 and 12 hours post-dose on Day 1 and at Week 4

  3. LS Mean Change From Baseline FEV1 to Peak FEV1 on Day 1 and at Weeks 1 to 3

    Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and peak FEV1 was defined as the maximum value in the 3 hours after dosing. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

    Time frame: Baseline (30 minutes before first administration on Day 1); 30 minutes post-dose on Day 1 and Weeks 1, 2 and 3

  4. LS Mean Change From Baseline FEV1 to Morning Trough FEV1 at Weeks 1 to 4

    Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and morning trough FEV1 was defined as the last pre-dose value. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

    Time frame: Baseline (30 minutes before first administration on Day 1) and morning pre-dose on Weeks 1, 2, 3 and 4

  5. LS Mean Change From Baseline to the Mean Weekly Evaluating Respiratory Symptoms of COPD (E-RS:COPD) Total Score at Weeks 1 to 4

    The E-RS scale consists of 11 questions, with 3 sub-domains of: breathlessness, cough and sputum, and chest symptoms. The E-RS sub-domain score was calculated as the sum from the relevant questions. The E-RS:COPD scale has a scoring range of 0 to 40. Higher scores indicates severe respiratory symptoms. Baseline was the mean over the 7 days prior to first intake of study treatment. Scores were derived weekly as the mean over 7 days prior to the visit, using only days where data was recorded. The E-RS:COPD was measured by daily electronic diary (e-diary).

    Time frame: Baseline and Weeks 1, 2, 3 and 4

  6. LS Mean Change From Baseline in the St George's Respiratory Questionnaire - COPD Specific (SGRQ-C) Total Score at Weeks 2 and 4

    Patients completed the SGRQ-C consisting of 40 items each weighted from 0 to a possible maximum of 100. Items 1-7 produced the symptoms score, 9-12 the activity score, and items 8, 10, 11, 13 and 14 the impacts score. Each component sub-score was calculated as a percentage of the summed weights of each item out of the sum of the maximum possible weight for that component (range 0-100). The total score was calculated by summing the weights to all positive responses in each component, where a positive item indicated the presence of symptoms, expressed as a percentage (range 0-100). Higher scores indicated a worse outcome. The SGRQ-C was measured at Week 2 and 4 visits.

    Time frame: Baseline, Weeks 2 and 4

  7. LS Mean Transition Dyspnea Index (TDI) Questionnaire Total Score at Weeks 2 and 4

    The TDI is a questionnaire that focussed on 3 sub-domains: functional impairment, magnitude of task and magnitude of effort. Sub-domain score was calculated as the sum from the related questions. Total score was calculated as the sum of the sub-domain scores. The TDI measures the change in dyspnea severity from the baseline as measured by the baseline dyspnea index. It was rated by 7 grades ranging from -3 (major deterioration) to +3 (major improvement). Higher scores indicate better outcome.

    Time frame: Weeks 2 and 4

  8. LS Mean Patient Global Assessment of Change (PGAC) Questionnaire Total Score at Weeks 2 and 4

    The PGAC is a single question assessment to determine whether patients noticed a change in their breathing since the start of the study. Patients were asked to respond to a PGAC question asking, "Compared with prior to the study start, how do you feel your breathing is?" on a scale of '1=much worse' to '5=much better', with '3=no change'. Higher scores indicate better outcome.

    Time frame: Weeks 2 and 4

  9. LS Mean Change From Baseline to the Mean Weekly Values Over Weeks 1 to 4 in Number of Puffs of Rescue Medication

    Use of rescue medication (albuterol) per visit was calculated as the LS mean use daily over total number of days between previous visit (inclusive) and the following visit. Baseline use was the mean over the last 7 days of the run-in phase (calculated as the sum of puffs taken, divided by number of days data has been recorded).

    Time frame: Baseline and Weeks 1, 2, 3 and 4

  10. LS Mean Change From Baseline Forced Vital Capacity (FVC) to Peak FVC on Day 1 and at Weeks 1 to 4

    Forced spirometry maneuvers including the FVC were used to assess pulmonary function. Baseline FVC was defined as the value of FVC assessed 30 minutes before first administration and peak FVC was defined as the maximum value in the 3 hours after dosing. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

    Time frame: Baseline (30 minutes before first administration on Day 1); 30 minutes post-dose on Day 1 and Weeks 1, 2, 3 and 4

  11. LS Mean Change From Baseline FVC to Average AUC0-3h FVC on Day 1 and at Weeks 1 to 4

    Forced spirometry maneuvers including the FVC were used to assess pulmonary function. Baseline FVC was defined as the value of FVC assessed 30 minutes before first administration and average AUC0-3h FVC was defined as area under the curve over 3 hours of the FVC, divided by 3 hours. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

    Time frame: Baseline (30 minutes before first administration on Day 1); 30 minutes and 1, 2, and 3 hours post-dose on Day 1 and Weeks 1, 2, 3 and 4

  12. LS Mean Change From Baseline FVC to Average AUC0-12h FVC on Day 1 and at Week 4

    Forced spirometry maneuvers including the FVC were used to assess pulmonary function. Baseline FVC was defined as the value of FVC assessed 30 minutes before first administration and average AUC0-12h FVC was defined as area under the curve over 12 hours of the FVC, divided by 12 hours. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

    Time frame: Baseline (30 minutes before first administration on Day 1); 30 minutes and 1, 2, 3, 4, 6, 8 and 12 hours post-dose on Day 1 and at Week 4

  13. LS Mean Change From Baseline FVC to Morning Trough FVC at Weeks 1 to 4

    Forced spirometry maneuvers including the FVC were used to assess pulmonary function. Baseline FVC was defined as the value of FVC assessed 30 minutes before first administration and morning trough FVC was defined as the last pre-dose value. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

    Time frame: Baseline (30 minutes before first administration on Day 1) and morning pre-dose on Weeks 1, 2, 3 and 4

  14. Steady-State Plasma Concentrations of Tiotropium on Day 1 and at Week 2

    Blood samples were taken to determine steady-state plasma concentrations of tiotropium prior to and following 14 days of treatment with RPL554.

    Time frame: Pre-dose on Day 1 and Week 2

  15. Steady-State Plasma Concentrations of RPL554 at Week 2

    Blood samples were taken to determine steady-state plasma concentrations of RPL554 following 14 days of treatment with RPL554.

    Time frame: Pre-dose at Week 2

  16. Number of Patients With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any undesirable experience occurring to a patient, or worsening in a patient, whether considered related to the study medication or not. All AEs which started after the first dose of study treatment or started prior to first dose of study treatment and worsened, based on the Investigator's assessment of severity, on or after first dose of study treatment were considered to be treatment-emergent. A serious adverse event is any adverse experience that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other important medical events.

    Time frame: TEAEs were collected from the first dose of study treatment up to 1 week after the final study visit at Week 4, approximately 5 weeks.

07

Results

Posted Oct 28, 2020
Limitations and caveats
One patient who was randomized to RPL554 0.375 mg group was dispensed wrong treatment kit and received RPL554 3 mg. Patients were classified according to randomized treatment for the FAS and actual treatment received for safety and PK analysis sets.

Participant flow

The study was conducted at 49 study centers in the United States of America between 01 May 2019 and 15 November 2019. Overall, 416 adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) on a stable background therapy of open-label tiotropium were randomized and 413 patients received double-blind study treatment.

Participant flow — Overall Study
MilestoneRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Started8385828284
Received treatment8383818284
Completed7370757679
Not completed1015765
Withdrew: Adverse event23001
Withdrew: Withdrawal by subject35221
Withdrew: Protocol violation56432
Withdrew: Lost to follow-up01010
Withdrew: Physician decision00101

Outcome measures

PrimaryLeast Square (LS) Mean Change From Baseline Forced Expiratory Volume in 1 Second (FEV1) to Peak FEV1 at Week 4

Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and peak FEV1 was defined as the maximum value in the 3 hours after dosing. Spirometry assessments were performed in accordance with American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · liters
Least Square (LS) Mean Change From Baseline Forced Expiratory Volume in 1 Second (FEV1) to Peak FEV1 at Week 4
litersRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Least Square (LS) Mean Change From Baseline Forced Expiratory Volume in 1 Second (FEV1) to Peak FEV1 at Week 40.1963 ± 0.026390.2100 ± 0.026760.2260 ± 0.026470.2431 ± 0.026310.1188 ± 0.02589
Statistical analysis
  • RPL554 3.0 mg vs Placebo · MMRM · p = 0.0008 (The mixed model for repeated measures (MMRM) model was used to model the change from baseline FEV1 to peak FEV1 using treatment, visit and treatment by visit interaction as fixed effect, patient as random effect and baseline FEV1 as the covariate.) · Ls mean difference: 0.1242 · 95% CI 0.0517 to 0.1968Estimates refer to the Week 4 from treatment by visit interaction.
  • RPL554 1.5 mg vs Placebo · MMRM · p = 0.0040 (The MMRM model was used to model the change from baseline FEV1 to peak FEV1 using treatment, visit and treatment by visit interaction as fixed effect, patient as random effect and baseline FEV1 as the covariate.) · Ls mean difference: 0.1072 · 95% CI 0.0344 to 0.1800Estimates refer to the Week 4 from treatment by visit interaction.
  • RPL554 0.75 mg vs Placebo · MMRM · p = 0.0148 (The MMRM model was used to model the change from baseline FEV1 to peak FEV1 using treatment, visit and treatment by visit interaction as fixed effect, patient as random effect and baseline FEV1 as the covariate.) · Ls mean difference: 0.0912 · 95% CI 0.0180 to 0.1643Estimates refer to the Week 4 from treatment by visit interaction.
  • RPL554 0.375 mg vs Placebo · MMRM · p = 0.0368 (The MMRM model was used to model the change from baseline FEV1 to peak FEV1 using treatment, visit and treatment by visit interaction as fixed effect, patient as random effect and baseline FEV1 as the covariate.) · Ls mean difference: 0.0775 · 95% CI 0.0048 to 0.1501Estimates refer to the Week 4 from treatment by visit interaction.
SecondaryLS Mean Change From Baseline FEV1 to Average Area Under the Curve Over 3 Hours (AUC0-3h) FEV1 on Day 1 and at Weeks 1 to 4

Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and average AUC0-3h FEV1 was defined as area under the curve over 3 hours of the FEV1, divided by 3 hours. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

Time frame:
Baseline (30 minutes before first administration on Day 1); 30 minutes and 1, 2, and 3 hours post-dose on Day 1 and Weeks 1, 2, 3 and 4
Reported as:
Least squares mean · liters
LS Mean Change From Baseline FEV1 to Average Area Under the Curve Over 3 Hours (AUC0-3h) FEV1 on Day 1 and at Weeks 1 to 4
litersRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Day 10.1533 ± 0.016000.1614 ± 0.016020.1810 ± 0.016200.2017 ± 0.016090.0654 ± 0.01590
Week 10.1118 ± 0.021290.1301 ± 0.021440.1308 ± 0.021430.1526 ± 0.021490.0246 ± 0.02107
Week 20.1154 ± 0.023080.1309 ± 0.023380.1433 ± 0.023340.1651 ± 0.023210.0304 ± 0.02285
Week 30.1156 ± 0.023230.1243 ± 0.023640.1444 ± 0.023430.1385 ± 0.023240.0294 ± 0.02297
Week 40.1095 ± 0.025380.1305 ± 0.025740.1394 ± 0.025440.1626 ± 0.025300.0369 ± 0.02488
SecondaryLS Mean Change From Baseline FEV1 to Average Area Under the Curve Over 12 Hours (AUC0-12h) FEV1 on Day 1 and at Week 4

Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and average AUC0-12h FEV1 was defined as area under the curve over 12 hours of the FEV1, divided by 12 hours. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

Time frame:
Baseline (30 minutes before first administration on Day 1); 30 minutes and 1, 2, 3, 4, 6, 8 and 12 hours post-dose on Day 1 and at Week 4
Reported as:
Least squares mean · liters
LS Mean Change From Baseline FEV1 to Average Area Under the Curve Over 12 Hours (AUC0-12h) FEV1 on Day 1 and at Week 4
litersRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Day 10.0795 ± 0.017670.0909 ± 0.017700.1020 ± 0.017900.1374 ± 0.017770.0282 ± 0.01756
Week 40.0359 ± 0.024550.0630 ± 0.024860.0640 ± 0.024510.0969 ± 0.024260.0096 ± 0.02413
SecondaryLS Mean Change From Baseline FEV1 to Peak FEV1 on Day 1 and at Weeks 1 to 3

Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and peak FEV1 was defined as the maximum value in the 3 hours after dosing. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

Time frame:
Baseline (30 minutes before first administration on Day 1); 30 minutes post-dose on Day 1 and Weeks 1, 2 and 3
Reported as:
Least squares mean · liters
LS Mean Change From Baseline FEV1 to Peak FEV1 on Day 1 and at Weeks 1 to 3
litersRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Day 10.2353 ± 0.019260.2426 ± 0.019300.2610 ± 0.019510.2852 ± 0.019380.1469 ± 0.01914
Week 10.1860 ± 0.023050.2026 ± 0.023220.2116 ± 0.023210.2353 ± 0.023260.1041 ± 0.02277
Week 20.1963 ± 0.024530.2121 ± 0.024830.2191 ± 0.024810.2421 ± 0.024660.1098 ± 0.02429
Week 30.1987 ± 0.025030.2006 ± 0.025440.2277 ± 0.025260.2197 ± 0.025050.1072 ± 0.02476
SecondaryLS Mean Change From Baseline FEV1 to Morning Trough FEV1 at Weeks 1 to 4

Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and morning trough FEV1 was defined as the last pre-dose value. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

Time frame:
Baseline (30 minutes before first administration on Day 1) and morning pre-dose on Weeks 1, 2, 3 and 4
Reported as:
Least squares mean · liters
LS Mean Change From Baseline FEV1 to Morning Trough FEV1 at Weeks 1 to 4
litersRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Week 1-0.0088 ± 0.02038-0.0354 ± 0.02058-0.0451 ± 0.02056-0.0216 ± 0.02081-0.0520 ± 0.02024
Week 2-0.0278 ± 0.02183-0.0696 ± 0.02243-0.0070 ± 0.022120.0136 ± 0.02220-0.0377 ± 0.02169
Week 3-0.0385 ± 0.02185-0.0630 ± 0.02254-0.0413 ± 0.02222-0.0232 ± 0.02205-0.0533 ± 0.02162
Week 4-0.0201 ± 0.02296-0.0348 ± 0.02356-0.0141 ± 0.023110.0054 ± 0.02306-0.0218 ± 0.02256
SecondaryLS Mean Change From Baseline to the Mean Weekly Evaluating Respiratory Symptoms of COPD (E-RS:COPD) Total Score at Weeks 1 to 4

The E-RS scale consists of 11 questions, with 3 sub-domains of: breathlessness, cough and sputum, and chest symptoms. The E-RS sub-domain score was calculated as the sum from the relevant questions. The E-RS:COPD scale has a scoring range of 0 to 40. Higher scores indicates severe respiratory symptoms. Baseline was the mean over the 7 days prior to first intake of study treatment. Scores were derived weekly as the mean over 7 days prior to the visit, using only days where data was recorded. The E-RS:COPD was measured by daily electronic diary (e-diary).

Time frame:
Baseline and Weeks 1, 2, 3 and 4
Reported as:
Least squares mean · units on a scale
LS Mean Change From Baseline to the Mean Weekly Evaluating Respiratory Symptoms of COPD (E-RS:COPD) Total Score at Weeks 1 to 4
units on a scaleRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Week 1-0.978 ± 0.3375-0.669 ± 0.3375-0.617 ± 0.3403-1.142 ± 0.3405-0.319 ± 0.3397
Week 2-0.873 ± 0.3916-0.471 ± 0.3932-0.597 ± 0.3921-0.598 ± 0.3952-0.102 ± 0.3908
Week 3-0.950 ± 0.3830-0.338 ± 0.3865-1.091 ± 0.3843-1.097 ± 0.3827-0.287 ± 0.3832
Week 4-1.690 ± 0.4337-0.593 ± 0.4412-1.226 ± 0.4346-1.071 ± 0.4357-0.228 ± 0.4320
SecondaryLS Mean Change From Baseline in the St George's Respiratory Questionnaire - COPD Specific (SGRQ-C) Total Score at Weeks 2 and 4

Patients completed the SGRQ-C consisting of 40 items each weighted from 0 to a possible maximum of 100. Items 1-7 produced the symptoms score, 9-12 the activity score, and items 8, 10, 11, 13 and 14 the impacts score. Each component sub-score was calculated as a percentage of the summed weights of each item out of the sum of the maximum possible weight for that component (range 0-100). The total score was calculated by summing the weights to all positive responses in each component, where a positive item indicated the presence of symptoms, expressed as a percentage (range 0-100). Higher scores indicated a worse outcome. The SGRQ-C was measured at Week 2 and 4 visits.

Time frame:
Baseline, Weeks 2 and 4
Reported as:
Least squares mean · units on a scale
LS Mean Change From Baseline in the St George's Respiratory Questionnaire - COPD Specific (SGRQ-C) Total Score at Weeks 2 and 4
units on a scaleRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Week 2-1.808 ± 1.1960-1.132 ± 1.2583-3.465 ± 1.2311-3.618 ± 1.2491-0.249 ± 1.2277
Week 4-4.387 ± 1.3087-2.400 ± 1.3732-4.870 ± 1.3480-4.163 ± 1.3479-0.116 ± 1.3195
SecondaryLS Mean Transition Dyspnea Index (TDI) Questionnaire Total Score at Weeks 2 and 4

The TDI is a questionnaire that focussed on 3 sub-domains: functional impairment, magnitude of task and magnitude of effort. Sub-domain score was calculated as the sum from the related questions. Total score was calculated as the sum of the sub-domain scores. The TDI measures the change in dyspnea severity from the baseline as measured by the baseline dyspnea index. It was rated by 7 grades ranging from -3 (major deterioration) to +3 (major improvement). Higher scores indicate better outcome.

Time frame:
Weeks 2 and 4
Reported as:
Least squares mean · units on a scale
LS Mean Transition Dyspnea Index (TDI) Questionnaire Total Score at Weeks 2 and 4
units on a scaleRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Week 21.682 ± 0.31831.285 ± 0.32631.582 ± 0.32291.589 ± 0.32551.421 ± 0.3202
Week 42.089 ± 0.34231.484 ± 0.34962.055 ± 0.34752.063 ± 0.34371.766 ± 0.3381
SecondaryLS Mean Patient Global Assessment of Change (PGAC) Questionnaire Total Score at Weeks 2 and 4

The PGAC is a single question assessment to determine whether patients noticed a change in their breathing since the start of the study. Patients were asked to respond to a PGAC question asking, "Compared with prior to the study start, how do you feel your breathing is?" on a scale of '1=much worse' to '5=much better', with '3=no change'. Higher scores indicate better outcome.

Time frame:
Weeks 2 and 4
Reported as:
Least squares mean · units on a scale
LS Mean Patient Global Assessment of Change (PGAC) Questionnaire Total Score at Weeks 2 and 4
units on a scaleRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Week 23.512 ± 0.08673.522 ± 0.08953.456 ± 0.08763.523 ± 0.08893.427 ± 0.0876
Week 43.553 ± 0.09223.543 ± 0.09443.536 ± 0.09323.577 ± 0.09223.506 ± 0.0909
SecondaryLS Mean Change From Baseline to the Mean Weekly Values Over Weeks 1 to 4 in Number of Puffs of Rescue Medication

Use of rescue medication (albuterol) per visit was calculated as the LS mean use daily over total number of days between previous visit (inclusive) and the following visit. Baseline use was the mean over the last 7 days of the run-in phase (calculated as the sum of puffs taken, divided by number of days data has been recorded).

Time frame:
Baseline and Weeks 1, 2, 3 and 4
Reported as:
Least squares mean · number of rescue medication puffs
LS Mean Change From Baseline to the Mean Weekly Values Over Weeks 1 to 4 in Number of Puffs of Rescue Medication
number of rescue medication puffsRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Week 1-0.510 ± 0.1384-0.580 ± 0.1407-0.539 ± 0.1395-0.629 ± 0.1412-0.556 ± 0.1386
Week 2-0.325 ± 0.1822-0.360 ± 0.1847-0.388 ± 0.1828-0.379 ± 0.1850-0.544 ± 0.1812
Week 3-0.302 ± 0.1726-0.139 ± 0.1765-0.647 ± 0.1736-0.558 ± 0.1742-0.504 ± 0.1724
Week 4-0.412 ± 0.1753-0.510 ± 0.1799-0.784 ± 0.1766-0.506 ± 0.1777-0.671 ± 0.1741
SecondaryLS Mean Change From Baseline Forced Vital Capacity (FVC) to Peak FVC on Day 1 and at Weeks 1 to 4

Forced spirometry maneuvers including the FVC were used to assess pulmonary function. Baseline FVC was defined as the value of FVC assessed 30 minutes before first administration and peak FVC was defined as the maximum value in the 3 hours after dosing. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

Time frame:
Baseline (30 minutes before first administration on Day 1); 30 minutes post-dose on Day 1 and Weeks 1, 2, 3 and 4
Reported as:
Least squares mean · liters
LS Mean Change From Baseline Forced Vital Capacity (FVC) to Peak FVC on Day 1 and at Weeks 1 to 4
litersRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Day 10.3463 ± 0.028570.3775 ± 0.028580.3852 ± 0.028920.4035 ± 0.028740.2241 ± 0.02840
Week 10.2839 ± 0.032810.3199 ± 0.033020.3065 ± 0.033020.3545 ± 0.033110.1717 ± 0.03242
Week 20.2597 ± 0.034010.3282 ± 0.034460.3070 ± 0.034400.3343 ± 0.034170.1524 ± 0.03368
Week 30.2744 ± 0.035120.3177 ± 0.035700.3176 ± 0.035440.3008 ± 0.035130.1626 ± 0.03475
Week 40.2706 ± 0.037240.3198 ± 0.037750.2951 ± 0.037290.3414 ± 0.037070.1736 ± 0.03647
SecondaryLS Mean Change From Baseline FVC to Average AUC0-3h FVC on Day 1 and at Weeks 1 to 4

Forced spirometry maneuvers including the FVC were used to assess pulmonary function. Baseline FVC was defined as the value of FVC assessed 30 minutes before first administration and average AUC0-3h FVC was defined as area under the curve over 3 hours of the FVC, divided by 3 hours. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

Time frame:
Baseline (30 minutes before first administration on Day 1); 30 minutes and 1, 2, and 3 hours post-dose on Day 1 and Weeks 1, 2, 3 and 4
Reported as:
Least squares mean · liters
LS Mean Change From Baseline FVC to Average AUC0-3h FVC on Day 1 and at Weeks 1 to 4
litersRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Day 10.2165 ± 0.023900.2397 ± 0.023900.2519 ± 0.024190.2715 ± 0.024040.0864 ± 0.02375
Week 10.1460 ± 0.030450.1890 ± 0.030650.1691 ± 0.030640.2039 ± 0.030740.0323 ± 0.03014
Week 20.1362 ± 0.032610.2010 ± 0.033020.1783 ± 0.032960.2104 ± 0.032790.0217 ± 0.03228
Week 30.1431 ± 0.033180.1860 ± 0.033720.1798 ± 0.033460.1739 ± 0.033210.0252 ± 0.03281
Week 40.1350 ± 0.036060.1928 ± 0.036540.1623 ± 0.036100.2134 ± 0.035940.0382 ± 0.03533
SecondaryLS Mean Change From Baseline FVC to Average AUC0-12h FVC on Day 1 and at Week 4

Forced spirometry maneuvers including the FVC were used to assess pulmonary function. Baseline FVC was defined as the value of FVC assessed 30 minutes before first administration and average AUC0-12h FVC was defined as area under the curve over 12 hours of the FVC, divided by 12 hours. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

Time frame:
Baseline (30 minutes before first administration on Day 1); 30 minutes and 1, 2, 3, 4, 6, 8 and 12 hours post-dose on Day 1 and at Week 4
Reported as:
Least squares mean · liters
LS Mean Change From Baseline FVC to Average AUC0-12h FVC on Day 1 and at Week 4
litersRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Day 10.0838 ± 0.025430.1294 ± 0.025430.1187 ± 0.025740.1514 ± 0.025580.0344 ± 0.02527
Week 40.0152 ± 0.034860.0838 ± 0.035290.0438 ± 0.034780.0982 ± 0.03443-0.0030 ± 0.03425
SecondaryLS Mean Change From Baseline FVC to Morning Trough FVC at Weeks 1 to 4

Forced spirometry maneuvers including the FVC were used to assess pulmonary function. Baseline FVC was defined as the value of FVC assessed 30 minutes before first administration and morning trough FVC was defined as the last pre-dose value. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

Time frame:
Baseline (30 minutes before first administration on Day 1) and morning pre-dose on Weeks 1, 2, 3 and 4
Reported as:
Least squares mean · liters
LS Mean Change From Baseline FVC to Morning Trough FVC at Weeks 1 to 4
litersRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Week 1-0.0159 ± 0.03028-0.0650 ± 0.03053-0.0887 ± 0.03053-0.0624 ± 0.03092-0.0617 ± 0.03008
Week 2-0.0647 ± 0.03190-0.0744 ± 0.03275-0.0458 ± 0.03231-0.0045 ± 0.03245-0.0614 ± 0.03170
Week 3-0.0966 ± 0.03354-0.0936 ± 0.03456-0.0857 ± 0.03410-0.0690 ± 0.03383-0.0969 ± 0.03318
Week 4-0.0390 ± 0.03323-0.0347 ± 0.03408-0.0570 ± 0.03344-0.0217 ± 0.03336-0.0198 ± 0.03264
SecondarySteady-State Plasma Concentrations of Tiotropium on Day 1 and at Week 2

Blood samples were taken to determine steady-state plasma concentrations of tiotropium prior to and following 14 days of treatment with RPL554.

Time frame:
Pre-dose on Day 1 and Week 2
Reported as:
Mean · picogram per milliliter (pg/mL)
Steady-State Plasma Concentrations of Tiotropium on Day 1 and at Week 2
picogram per milliliter (pg/mL)RPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Day 12.8 ± 1.182.1 ± 2.981.9 ± 1.42.4 ± 3.562.4 ± 3.06
Week 22.2 ± 3.852.3 ± 3.561.9 ± 1.582.0 ± 2.222.2 ± 2.13
SecondarySteady-State Plasma Concentrations of RPL554 at Week 2

Blood samples were taken to determine steady-state plasma concentrations of RPL554 following 14 days of treatment with RPL554.

Time frame:
Pre-dose at Week 2
Reported as:
Mean · pg/mL
Steady-State Plasma Concentrations of RPL554 at Week 2
pg/mLRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Steady-State Plasma Concentrations of RPL554 at Week 237.3 ± 58.8453.7 ± 51.71107.9 ± 92.98170.6 ± 154.3NA ± NA
SecondaryNumber of Patients With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any undesirable experience occurring to a patient, or worsening in a patient, whether considered related to the study medication or not. All AEs which started after the first dose of study treatment or started prior to first dose of study treatment and worsened, based on the Investigator's assessment of severity, on or after first dose of study treatment were considered to be treatment-emergent. A serious adverse event is any adverse experience that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other important medical events.

Time frame:
TEAEs were collected from the first dose of study treatment up to 1 week after the final study visit at Week 4, approximately 5 weeks.
Reported as:
Count of participants · Participants
Number of Patients With Treatment Emergent Adverse Events (TEAEs)
ParticipantsRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Any TEAE1215141817
Any TEAE leading to drug discontinuation23001
Any drug-related TEAE13224
Any serious TEAE01020
Any serious drug-related TEAE00000
Any serious TEAE leading drug discontinuation01000
Any TEAE leading to death00000

Adverse events

Collected over TEAEs were collected from the first dose of study treatment up to 1 week after the final study visit at Week 4, approximately 5 weeks.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RPL554 0.375 mg0/82 (0%)0/82 (0%)6/82 (7.3%)
RPL554 0.75 mg0/83 (0%)1/83 (1.2%)9/83 (10.8%)
RPL554 1.5 mg0/81 (0%)0/81 (0%)4/81 (4.9%)
RPL554 3.0 mg0/83 (0%)2/83 (2.4%)8/83 (9.6%)
Placebo0/84 (0%)0/84 (0%)5/84 (6%)
Most frequent serious events
Most frequent serious events
EventRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Jaw fractureInjury, poisoning and procedural complications0/821/830/810/830/84
SyncopeNervous system disorders0/820/830/811/830/84
Alcohol abusePsychiatric disorders0/820/830/811/830/84
Chronic kidney diseaseRenal and urinary disorders0/821/830/810/830/84
Most frequent other events
Most frequent other events
EventRPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders3/822/830/813/830/84
GastroenteritisInfections and infestations0/820/832/810/830/84
HeadacheNervous system disorders2/821/831/812/831/84
DyspnoeaRespiratory, thoracic and mediastinal disorders0/821/830/812/830/84
Blood creatinine increasedInvestigations1/822/831/810/830/84
Muscle spasmsMusculoskeletal and connective tissue disorders0/822/830/810/830/84
Oral candidiasisInfections and infestations0/821/830/811/832/84
NasopharyngitisInfections and infestations0/820/830/811/832/84

Baseline characteristics

All Patients Randomized Set included all patients who provided informed consent and who were randomized to study treatment.

Age, Categorical
Age, Categorical(Participants)RPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlaceboTotal
<=18 years000000
Between 18 and 65 years4440454147217
>=65 years3945374137199
Age, Continuous
Age, Continuous(years)RPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlaceboTotal
Mean64.2 ± 7.8665.5 ± 8.3363.8 ± 7.6764.5 ± 7.9263.6 ± 8.4164.3 ± 8.03
Sex: Female, Male
Sex: Female, Male(Participants)RPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlaceboTotal
Female5148514544239
Male3237313740177
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlaceboTotal
Hispanic or Latino111238
Not Hispanic or Latino8284818081408
Unknown or Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RPL554 0.375 mgRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgPlaceboTotal
American Indian or Alaska Native000000
Asian000000
Black or African American10796941
Native Hawaiian or Other Pacific Islander000000
White7378737675375
Other000000
08

Study locations

50 sites
  • Pinnacle Research Group, LLC
    Anniston, Alabama 36207, United States
  • California Research Medical Group, Inc
    Fullerton, California 92835, United States
  • Southern California Institute For Respiratory Diseases, Inc.
    Los Angeles, California 90048, United States
  • Innovative Clinical Research
    Lafayette, Colorado 80026, United States
  • Meris Clinical Research
    Brandon, Florida 33511, United States
  • Clinical Research of West Florida
    Clearwater, Florida 33765, United States
  • Pulmonary Disease Specialists, PA d/b/a PDS Research
    Kissimmee, Florida 34741, United States
  • Medical Research of Central Florida, LLC
    Leesburg, Florida 34748, United States
  • Clinical Trials of Florida, LLC
    Miami, Florida 33186, United States
  • Peninsula Research, Ormond Beach, LLC
    Ormond Beach, Florida 32174, United States
  • Medsol Clinical Research Center, Inc
    Port Charlotte, Florida 33952, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Pasadena Center for Medical Research, LLC
    Saint Petersburg, Florida 33707, United States
  • Florida Pulmonary Research Institute, LLC
    Winter Park, Florida 32789, United States
  • Columbus Regional Research Institute
    Columbus, Georgia 31904, United States
  • VitaLink Research - Hamilton Mill
    Dacula, Georgia 30019, United States
  • VitaLink Research - Duluth
    Duluth, Georgia 30096, United States
  • Gwinnett Biomedical Research
    Lawrenceville, Georgia 30046, United States
  • IACT Health
    Rincon, Georgia 31326, United States
  • Vitalink
    Winder, Georgia 30680, United States
  • Genesis Clinical Research and Consulting, LLC
    Fall River, Massachusetts 02723, United States
  • Pulmonary Research Institute of Southeast Michigan
    Farmington Hills, Michigan 48336, United States
  • Cities Research Center
    Fridley, Minnesota 34741, United States
  • American Health Research
    Charlotte, North Carolina 28078, United States
  • Clinical Research of Gastonia
    Gastonia, North Carolina 28054, United States
  • Research Carolina of Huntersville
    Huntersville, North Carolina 28078, United States
  • Clinical Research of Lake Norman
    Mooresville, North Carolina 28117, United States
  • New Horizons Clinical Research
    Cincinnati, Ohio 45242, United States
  • Aventiv Research, Inc
    Columbus, Ohio 43213, United States
  • Aventiv Research, Inc
    Dublin, Ohio 43016, United States
  • Crisor, LLC
    Medford, Oregon 97504, United States
  • Vitalink Research - Anderson
    Anderson, South Carolina 29621, United States
  • Lowcountry Lung and Critical Care, PA
    Charleston, South Carolina 29406, United States
  • VitaLink-Columbia
    Columbia, South Carolina 33765, United States
  • VitaLink Research - Easley
    Easley, South Carolina 29640, United States
  • Piedmont Research Partners, LLC
    Fort Mill, South Carolina 29707, United States
  • VitaLink Research-Gaffney
    Gaffney, South Carolina 29340, United States
  • VitaLink Research-Greenville
    Greenville, South Carolina 29615, United States
  • VitaLink Research-UPSTATE
    Greenville, South Carolina 29615, United States
  • Clinical Research of Charleston
    Mount Pleasant, South Carolina 29464, United States
  • Clinical Research of Rock Hill
    Rock Hill, South Carolina 29732, United States
  • Vitalink Research-Seneca
    Seneca, South Carolina 29678, United States
  • Fusion Clinical Research of Spartanburg, LLC
    Spartanburg, South Carolina 29301, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29301, United States
  • Vitalink Research-Spartanburg
    Spartanburg, South Carolina 29303, United States
  • VitaLink Research - Union
    Union, South Carolina 29379, United States
  • New Phase Research & Development
    Knoxville, Tennessee 37909, United States
  • FMC Science, LLC
    Lampasas, Texas 76550, United States
  • DCOL Center for Clinical Research
    Longview, Texas 75605, United States
  • Metroplex Pulmonary and Sleep Center
    McKinney, Texas 75069, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Nov 2019, 6 months.

Results were first posted in Oct 2020, 11 months after primary completion.

Of 120 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 6 months is below that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2019
First posted
May 3, 2019
StartActual
May 1, 2019
Primary completionActual
Nov 15, 2019
CompletionActual
Nov 15, 2019
Results first posted
Oct 28, 2020
Last update
Nov 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03937479
Lead sponsor
Verona Pharma plc
Collaborators
Iqvia Pty Ltd, LGC Limited
Responsible party
Sponsor
First posted
May 3, 2019
Start date
May 1, 2019
Primary completion
Nov 15, 2019
Completion
Nov 15, 2019
Results posted
Oct 28, 2020
Last update
Nov 20, 2020

Study contacts

Gary Ferguson
principal investigator · Pulmonary Research Institute of Southeast Michigan

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion